March 4, 2025 - 12:22
Recent updates have highlighted significant advancements in the clinical development of AXN-2510/IMM2510, particularly in the treatment of relapsed and refractory non-small cell lung cancer (NSCLC) in China. ImmuneOnco is expected to release clinical data related to the monotherapy of AXN-2510/IMM2510 in the first half of 2025. This data is eagerly anticipated as it could provide valuable insights into the efficacy of the treatment.
Furthermore, the enrollment of patients with first-line NSCLC for a trial combining AXN-2510/IMM2510 with chemotherapy is projected to begin in the second quarter of 2025. Initial clinical results from this trial are expected to be available in the latter half of 2025, potentially paving the way for new treatment protocols.
In addition, plans are underway to initiate a U.S. clinical study of AXN-2510/IMM2510 in conjunction with chemotherapy for first-line NSCLC patients, with expectations for this to commence before the end of the year. These developments reflect a growing commitment to advancing therapies for NSCLC and improving patient outcomes.
